AbbVie Reports Results of Skyrizi (risankizumab) in P-III Induction Studies for Crohn's Disease
Shots:
- The P-III ADVANCE & MOTIVATE studies involves assessing of Risankizumab (600/1200mg) vs PBO in adult patients with mod. to sev. CD who had an inadequate response/ were intolerant to conventional and/or biologic therapy & patients who had responded inadequately or were intolerant to biologic therapy respectively
- Results: @12wks. clinical remission as per CDAI (45%/42% vs 25%) & (42%/41% vs 19%); clinical remission per PRO-2 (43%/41% vs 21%) & (35%/39% vs 19%); endoscopic response (40%/32% vs 12%) & (29%/34% vs 11%) respectively
- Skyrizi is an IL-23 inhibitor- being evaluated in mod. to sev. CD and other immune-mediated conditions
Ref: AbbVie| Image:abbvie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com